2-amino-hexan-1-ol; hydrochloride | 89585-17-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-amino-hexan-1-ol; hydrochloride
• 英文别名: 2-aminohexanol hydrochloride；trans-2-aminohexanol hydrochloride；1-Hexanol, 2-amino-, hydrochloride (1:1)；2-aminohexan-1-ol;hydrochloride
• CAS: 89585-17-1
• 化学式: C₆H₁₅NO*ClH
• 分子量: 153.652
• InChiKey: SKICEFAZSRNYCY-UHFFFAOYSA-N

物化性质

• 熔点：
  93-94.5 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.92
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-amino-hexan-1-ol; hydrochloride 、 间氯苯异氰酸酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以93%的产率得到1-(3-chloro-phenyl)-3-(1-hydroxymethyl-pentyl)-urea
  参考文献：
  名称：

  [EN] IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE
  [FR] INHIBITEURS AMELIORES DE L'EPOXYDE HYDROLASE SOLUBLE

  摘要：

  公开号：

  WO2006045119A3

文献信息

• FUSED HETEROAROMATIC PYRROLIDINONES
  申请人：Arikawa Yasuyoshi

  公开号：US20110152273A1

  公开（公告）日：2011-06-23

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L 1 , L 2 , R 1 , R 2 , R 3 , and R 4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

  本公开涉及公式1的化合物及其药学上可接受的盐，其中G、L1、L2、R1、R2、R3和R4在说明书中有定义。本公开还涉及制备公式1化合物的材料和方法，含有它们的药物组合物，以及它们在治疗涉及免疫系统和炎症的紊乱、疾病和病况，包括类风湿关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他需要抑制SYK的紊乱、疾病和病况的用途。
• Inhibitors for the soluble epoxide hydrolase
  申请人：Hammock D. Bruce

  公开号：US20060270609A1

  公开（公告）日：2006-11-30

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了可用于治疗疾病的可溶性环氧酶（sEH）抑制剂，其中包含多个药效团。
• FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS
  申请人：Arikawa Yasuyoshi

  公开号：US20130116260A1

  公开（公告）日：2013-05-09

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L 1 , L 2 , R 1 , R 2 , R 3 , and R 4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

  本发明涉及式1的化合物及其药学上可接受的盐，其中G、L1、L2、R1、R2、R3和R4如规范中所定义。本公开还涉及制备式1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗涉及免疫系统和炎症的疾病、疾患和病况，包括类风湿性关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他需要抑制SYK的疾病、疾患和病况。
• PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3489236A1

  公开（公告）日：2019-05-29

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

  公开了式 1 的化合物、 及其药学上可接受的盐类，其中 G、L1、L2、R1、R2、R3 和 R4 的定义见说明书。本公开还涉及制备式 1 化合物的材料和方法、含有它们的药物组合物，以及它们在治疗涉及免疫系统和炎症的紊乱、疾病和病症方面的用途，包括类风湿性关节炎、血液恶性肿瘤、上皮癌（即癌），以及其它需要抑制 SYK 的紊乱、疾病和病症。
• Boron-containing small molecules as antiprotozoal1 agents
  申请人：MMV MEDICINES FOR MALARIA VENTURE

  公开号：US10011616B2

  公开（公告）日：2018-07-03

  This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. Formula (I) and (II)

  本发明主要提供了用于治疗原生动物感染的新型化合物、含有此类化合物的药物组合物，以及这些化合物与至少一种额外的治疗有效药物的组合物。式 (I) 和 (II)